Following the successful market entry in several European countries, Proteomedix entered into an agreement for Labcorp, a leading global life sciences company, to develop and commercialize the Proclarix Prostate Specific Antigen (PSA) test in the U.S.. Co-founder Ralph Schiess will lead the company through the growth phase. He took over as CEO on 1 June.
Proclarix is designed to help determine the risk of clinically significant prostate cancer for men with an elevated total PSA and a digital rectal examination that indicates elevated prostate volume, but who are not suspected of having cancer. In appropriate cases, the test provides a non-invasive alternative to a prostate biopsy, which can have significant side effects.
Proclarix, a CE-IVDR marked product available in several countries across Europe, is seeing adoption in patient management as it is recommended by both the European Association of Urology (EAU) and the American Urology Association (AUA) guidelines for the early detection of prostate cancer. The largest laboratories working with Proclarix are in Switzerland, Germany and Italy. The test is also used in Finland and England.
Proteomedix is now expanding to the US with an agreement for Labcorp, to develop and commercialize Proclarix there. “In the USA, Proclarix is not offered as a kit, but as a service. Therefore, our partner is developing a laboratory test based on Proclarix”, explains Proteomedix CEO Ralph Schiess. This is the first partnership of this kind of the Schlieren-based medtech company. However others maybe added: “We are currently evaluating possible partners for Europe and Asia as well as the rest of the world”, says Schiess.
Proteomedix co-founder Ralph Schiess took over as CEO on 1 June. "I’m excited to lead the company in this next phase as we expand the use of Proclarix," said Ralph Schiess and added: “We want to further leverage the potential of our biomarker platform becoming a multiomics leader in the oncology sector. Additionally, we intend to build on top of our existing collaboration to commercializing Proclarix in the U.S. and expand our commercial partnering activities to other markets/territories. With the extension of the Board of Directors with Werner Böing, former Chief Information Officer at Roche Diagnostics, we are well prepared for the digital change of future diagnostics."
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines